2019 Aspen Lung Conference: Exploring new therapeutic pathways in pulmonary hypertension: metabolism, proliferation, and personalized medicine

2019阿斯彭肺会议：探索肺动脉高压的新治疗途径：代谢、增殖和个性化医疗

• 批准号: 9763199
• 负责人: MARJORIE Patricia GEORGE
• 金额: $ 3万
• 依托单位: NATIONAL JEWISH HEALTH
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9763199
• 关键词: Award; Basic Science; Blood Vessels; Cardiology; Cell Proliferation; Clinical; Clinical Research; Clinical Trials; Ensure; Faculty; Female; Functional disorder; Future; Generations; Goals; Grant; Hypoxia; International; Lung; Metabolism; Minority; Molecular; Neoplasms; Oral; Pathogenesis; Pathology; Pathway interactions; Patients; Phenotype; Publishing; Pulmonary Hypertension; Pulmonology; Research; Research Personnel; Risk; Scientist; Signal Transduction; Translating; Translational Research; Travel; Underrepresented Minority; Woman; base; chemotherapy; effective therapy; ethnic minority population; interest; lectures; neoplastic; novel therapeutics; oncology; personalized medicine; posters; pre-clinical; programs; response; symposium

ABSTRACT The PH field has increasingly recognized that the pulmonary vascular pathology present in pulmonary hypertension (PH) has neoplastic-like features, including the identification of key shared pathophysiology commonalities and has now spawned clinical trials of chemotherapy agents in patients with PH. The 2019 Thomas L. Petty Aspen Lung Conference will explore the common mechanisms found in neoplasia and PH, with the overall goal of translating our understanding of cellular metabolism, proliferation and signaling into more effective therapies for patients with PH. The title of the conference is “Exploring new therapeutic pathways in pulmonary hypertension: metabolism, proliferation, and personalized medicine”. The four days of the conference will integrate basic, translational, and clinical approaches while focusing on the following themes in PH: Cellular Metabolism, Hypoxia Signaling, Aberrant Cellular Proliferation and Personalized Medicine. We have identified 12 speakers who are outstanding scientists in their fields, who will present State of the Art lectures on these topics. Each of these presentations will be 35 minutes in duration, followed by 25 minutes for discussion to ensure a lively interaction which is a hallmark of this conference. We have a particular emphasis on including female and ethnic minority State of the Art speakers (54% and 38% in the planned program, respectively). Inclusion of trainees and junior faculty is emphasized by having two 15-minute oral abstracts following each State of the Art speaker (24 total), that will be selected from submitted abstracts. There will be two evening poster sessions for further presentation opportunities by junior faculty and trainees. The final presentation is by a Conference Summarizer, who reviews the impact and common themes of the entire conference. The conference proceedings are subsequently published for widespread dissemination. Two travel grants are awarded to female and under-represented minority abstract applicants based on scientific excellence. The conference has the following objectives: 1) To provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding fundamental concepts in the pathogenesis and treatment of PH. 2) To stimulate interactions between the fields of pulmonology, cardiology and oncology with the goal of identifying emerging, shared interests that will lead to more efficient and productive research. 3) To advance our understanding of clinical and molecular PH pathobiology in order to translate preclinical findings to more effective, personalized therapies. 4) To challenge and thereby stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the field of PH pathobiology. In summary, the conference distinguishes itself from other conferences in the PH field by serving as a “think tank” to actively discuss the current state of the field and identify the future directions for basic, translation and clinical research in PH.

摘要 PH领域越来越认识到，肺血管病理学存在于肺动脉中， 高血压（PH）具有肿瘤样特征，包括确定关键的共同病理生理学 共同点，现在已经催生了PH患者化疗药物的临床试验。2019年 托马斯湖Petty白杨肺部会议将探讨肿瘤和PH中发现的共同机制， 我们的总体目标是将我们对细胞代谢、增殖和信号传导的理解转化为更多 会议的主题是“探索PH患者的新治疗途径”。 肺动脉高压：代谢、增殖和个性化医疗”。会议的四天 将整合基础，转化和临床方法，同时专注于PH中的以下主题：细胞 代谢，缺氧信号，异常细胞增殖和个性化医疗。我们已经确定 12位演讲者是各自领域的杰出科学家，他们将在这些领域提供最先进的讲座 话题每一个演讲将持续35分钟，然后是25分钟的讨论， 确保活跃的互动，这是本次会议的一个特点。我们特别强调， 女性和少数民族的最新演讲者（在计划方案中分别占54%和38%）。 包括学员和初级教员强调有两个15分钟的口头摘要后，每个 最先进的演讲者（共24名），将从提交的摘要中选出。将有两个晚上的海报 为初级教师和学员提供更多的演讲机会。最后的介绍是由一个 会议总结者，负责审查整个会议的影响和共同主题。会议 会议记录随后出版，供广泛传播。向妇女提供两笔旅费赠款 和代表性不足的少数民族基于科学卓越的抽象申请人。裁谈会有 以下目标：1）为领先的基础，翻译和临床研究人员提供国际论坛 就PH的发病机制和治疗的基本概念交换意见。2）刺激 肺病学、心脏病学和肿瘤学领域之间的相互作用， 共同的利益，这将导致更有效和更富有成效的研究。3)为了增进我们对 临床和分子PH病理生物学，以便将临床前发现转化为更有效，个性化的 治疗4)挑战并激发受训者的科学兴趣，吸引新一代 PH病理生物学领域的初级研究人员。总之，会议区别于 在PH领域的其他会议作为一个“智囊团”，积极讨论该领域的现状， 确定PH基础、转化和临床研究的未来方向。